Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 4
2009 4
2010 5
2011 5
2012 8
2013 8
2014 7
2015 8
2016 3
2017 7
2018 9
2019 6
2020 4
2021 9
2022 12
2023 2
2024 4
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Results by year

Filters applied: . Clear all
Page 1
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Dorman SE, et al. N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400. N Engl J Med. 2021. PMID: 33951360 Free PMC article. Clinical Trial.
Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.
Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, Mabwe S, Makhethe L, Erasmus M, Toefy A, Mulenga H, Hanekom WA, Self SG, Bekker LG, Ryall R, Gurunathan S, DiazGranados CA, Andersen P, Kromann I, Evans T, Ellis RD, Landry B, Hokey DA, Hopkins R, Ginsberg AM, Scriba TJ, Hatherill M; C-040-404 Study Team. Nemes E, et al. N Engl J Med. 2018 Jul 12;379(2):138-149. doi: 10.1056/NEJMoa1714021. N Engl J Med. 2018. PMID: 29996082 Free PMC article. Clinical Trial.
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis.
Chang VK, Imperial MZ, Phillips PPJ, Velásquez GE, Nahid P, Vernon A, Kurbatova EV, Swindells S, Chaisson RE, Dorman SE, Johnson JL, Weiner M, Jindani A, Harrison T, Sizemore EE, Whitworth W, Carr W, Bryant KE, Burton D, Dooley KE, Engle M, Nsubuga P, Diacon AH, Nhung NV, Dawson R, Savic RM; AIDS Clinical Trial Group; Tuberculosis Trials Consortium. Chang VK, et al. Nat Commun. 2024 Oct 30;15(1):9400. doi: 10.1038/s41467-024-53273-7. Nat Commun. 2024. PMID: 39477924 Free PMC article. Clinical Trial.
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis.
Tait DR, Hatherill M, Van Der Meeren O, Ginsberg AM, Van Brakel E, Salaun B, Scriba TJ, Akite EJ, Ayles HM, Bollaerts A, Demoitié MA, Diacon A, Evans TG, Gillard P, Hellström E, Innes JC, Lempicki M, Malahleha M, Martinson N, Mesia Vela D, Muyoyeta M, Nduba V, Pascal TG, Tameris M, Thienemann F, Wilkinson RJ, Roman F. Tait DR, et al. Among authors: tameris m. N Engl J Med. 2019 Dec 19;381(25):2429-2439. doi: 10.1056/NEJMoa1909953. Epub 2019 Oct 29. N Engl J Med. 2019. PMID: 31661198 Free article. Clinical Trial.
T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection.
Musvosvi M, Huang H, Wang C, Xia Q, Rozot V, Krishnan A, Acs P, Cheruku A, Obermoser G, Leslie A, Behar SM, Hanekom WA, Bilek N, Fisher M, Kaufmann SHE, Walzl G, Hatherill M, Davis MM, Scriba TJ; Adolescent Cohort Study team; GC6-74 Consortium. Musvosvi M, et al. Nat Med. 2023 Jan;29(1):258-269. doi: 10.1038/s41591-022-02110-9. Epub 2023 Jan 5. Nat Med. 2023. PMID: 36604540 Free PMC article.
Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.
Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Kimbung Mbandi S, Borate B, Mendelsohn SC, Hadley K, Hikuam C, Kaskar M, Musvosvi M, Bilek N, Self S, Sumner T, White RG, Erasmus M, Jaxa L, Raphela R, Innes C, Brumskine W, Hiemstra A, Malherbe ST, Hassan-Moosa R, Tameris M, Walzl G, Naidoo K, Churchyard G, Hatherill M; CORTIS-01 Study Team. Scriba TJ, et al. Among authors: tameris m. Lancet Infect Dis. 2021 Mar;21(3):354-365. doi: 10.1016/S1473-3099(20)30914-2. Epub 2021 Jan 25. Lancet Infect Dis. 2021. PMID: 33508224 Free PMC article. Clinical Trial.
Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b-2a, double-blind, dose-escalation, randomised controlled trial.
Luabeya AKK, Rozot V, Imbratta C, Ratangee F, Shenje J, Tameris M, Mendelsohn SC, Geldenhuys H, Fisher M, Musvosvi M, Young C, Mulenga H, Bilek N, Mabwe S, Jelsbak IM, Rodríguez E, Puentes E, Doce J, Aguilo N, Martin C, Pillay C, Tait D, Russell M, Van Der Merve A, Rutkowski K, Hunt D, Ginsberg A, Scriba TJ, Hatherill M; A050 team. Luabeya AKK, et al. Among authors: tameris m. Lancet Glob Health. 2025 Jun;13(6):e1030-e1042. doi: 10.1016/S2214-109X(25)00046-4. Epub 2025 Apr 15. Lancet Glob Health. 2025. PMID: 40250461 Free article. Clinical Trial.
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial.
Shinde V, Lombard Koen A, Hoosain Z, Archary M, Bhorat Q, Fairlie L, Lalloo U, Masilela MSL, Moodley D, Hanley S, Fouche LF, Louw C, Tameris M, Singh N, Goga A, Dheda K, Grobbelaar C, Joseph N, Lombaard JJ, Mngqibisa R, Bhorat AE, Benadé G, Lalloo N, Pitsi A, Vollgraaff PL, Luabeya A, Esmail A, Petrick FG, Oommen Jose A, Foulkes S, Ahmed K, Thombrayil A, Kalonji D, Cloney-Clark S, Zhu M, Bennett C, Albert G, Marcheschi A, Plested JS, Neal S, Chau G, Cho I, Fries L, Glenn GM, Madhi SA; 2019nCoV-501 Study Group. Shinde V, et al. Among authors: tameris m. Hum Vaccin Immunother. 2024 Dec 31;20(1):2425147. doi: 10.1080/21645515.2024.2425147. Epub 2024 Dec 12. Hum Vaccin Immunother. 2024. PMID: 39666396 Free PMC article. Clinical Trial.
PET/CT guided tuberculosis treatment shortening: a randomized trial.
Malherbe ST, Chen RY, Yu X, Smith B, Liu X, Gao J, Diacon AH, Dawson R, Tameris M, Zhu H, Qu Y, Jin H, Pan S, Dodd LE, Wang J, Goldfeder LC, Cai Y, Arora K, Vincent J, Narunsky K, Serole K, Goliath RT, Da Costa L, Taliep A, Aziz S, Daroowala R, Thienemann F, Mukasa S, Court R, Sossen B, Ahlers P, Mendelsohn SC, White L, Gouel A, Lau CY, Hassan S, Liang L, Duan H, Moghaddam GK, Paripati P, Lahouar S, Harris M, Wollenberg K, Jeffrey B, Tartakovsky M, Rosenthal A, Duvenhage M, Armstrong DT, Song T, Winter J, Gao Q, Via LE, Wilkinson RJ, Walzl G, Barry CE 3rd. Malherbe ST, et al. Among authors: tameris m. medRxiv [Preprint]. 2024 Oct 4:2024.10.03.24314723. doi: 10.1101/2024.10.03.24314723. medRxiv. 2024. PMID: 39802795 Free PMC article. Preprint.
107 results